Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TNBC. However, u
TPS629#Background:Neoadjuvant chemoimmunotherapy is recommended for patients with high risk early stage TNBC. The 5 drug KEYNOTE-522 neoadjuvant chemoimmunotherapy regimen involves 5-6 months of treatment and is associated with suboptimal treatment completion due to toxicity. Approaches to deescalate ...
regardless of the pCR outcome, as a standard-of-care treatment regimen for patients with high-risk, early-stage TNBC,” Peter Schmid, FRCP, MD, PhD, professor of cancer medicine; centre lead, Centre of Experimental Cancer Medicine;
Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TNBC. However, up to 70% of TNBC patients have significa...
Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer View More Latest Conference CoverageAdvertise About OncLive Editorial Board MJH Life Sciences brands Contact Us Privacy ...
Latest Conference Coverage HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC Elacestr...
"Here we show that the improved pCR rates translated into improved disease-free survival," continued von Minckwitz. "Patients with TNBC who received carboplatin as part of their neoadjuvant chemotherapy regimen were almost half as likely to have had disease relapse at three years after starting tre...
For the current analysis, patients were stratified by PD-L1 CPS in the tumor, including over 320 patients with CPS ≥ 10 and by accompanying chemotherapy regimen. In the overall intention-to-treat (ITT) population (n = 847), median PFS was longer with pembrolizumab plus chemotherapy versus pl...
The mice bearing bilateral 4T1 or EMT6 tumor were randomly assigned into eight groups, and received the same treatment regimen as the antitumor experiment. For the detection of DCs maturation in 4T1 model, the next day after the first treatment, the inguinal lymph nodes of each treated mouse ...
Latest Conference Coverage HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage ...